Signs and symptoms of respiratory syncytial virus infection most commonly appear about four to six days after exposure to the virus.
RSV is riskier for young children, but it can also be serious for older people and those who have other health problems.
Adults who get infected with RSV usually have mild or no symptoms. Symptoms are usually consistent with an upper respiratory tract infection which can include rhinorrhea, pharyngitis, cough, headache, fatigue, and fever.
Disease usually lasts less than five days. Some adults, however, may have more severe symptoms consistent with a lower respiratory tract infection, such as pneumonia.
Those at high risk for severe illness from RSV include: 65 years and older, history of Asthma, COPD, CHF and if immunocompromised.
rRT-PCR is more sensitive than culture and antigen testing.
Palivizumab is a monoclonal antibody recommended for immunoprophylaxis only for high-risk infants and young children.
FDA advisers recommended this week that the agency approve two RSV vaccines for older people, one from Pfizer and another from Glaxo.
Pfizer vaccine is being prepared for both infants through maternal immunization and older adults to help protect against RSV.
After FDA approval, the CDC must recommend the shots before they become available to the public.